Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Skin barrier dysfunction mutations vary by race, disease persistence in children with AD

Key clinical point: Genetic variants associated with skin barrier dysfunction varied significantly by race and by influence on disease persistence in a cohort of children with atopic dermatitis

Major finding: White children were more than twice as likely as African American children to harbor a filaggrin gene loss of function. Some variations were more common in white children, while others were exclusively found in African American children.

Study details: An analysis of DNA from 714 children enrolled in the Pediatric Eczema Elective Registry.

Disclosures: The study was supported by a grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. The Pediatric Eczema Elective Registry cohort is funded by Valeant Pharmaceuticals. The lead author reported receiving research funding as the principal investigator via the trustees of the University of Pennsylvania, and receiving funding from the National Institutes of Health and Valeant; disclosures not related to the study included consulting activities primarily as a member of a data monitoring or scientific advisory boards for several pharmaceutical companies.

Citation:

Margolis DJ et al. JAMA Dermatol. 2019 Jul 31. doi: 10.1011/jamadermatol.2019.1946.